A global health consortium required support in attracting greater industry investment into the traditionally underfunded area of Strep A vaccine development.
The Alzheimer Society of Canada—the national body of a federation of dozens of provincial societies and regional chapters—needed a strategy to deliver a newly-approved mandate.
The Ontario Brain Institute (OBI) needed to define its strategic direction and articulate its value to policymakers to ensure continued government support for brain research.
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
The International AIDS Society (IAS) required support to develop a 5-year strategy for the Global HIV Vaccine Enterprise (the Enterprise)—a long-time convenor and facilitator for the HIV vaccine R&D field.
The Canadian Cancer Research Alliance (CCRA) wanted to better understand the cancer clinical trial landscape in Canada, and in particular, the contribution of its initiatives to promoting access to trials.
The International Vaccine Institute in South Korea and the Saudi Ministry of Health required strategic and facilitation support to advance a collaborative approach to MERS-CoV vaccine development.
Shift Health was engaged by a newly formed government-funded agency to develop a foreign direct investment (FDI) attraction strategy for the Toronto Region’s healthcare and life sciences cluster.
MaRS Innovation (now called Toronto Innovation Acceleration Partners – TIAP) sought to develop a novel approach to investing in research breakthroughs and bringing them to market.